Hollace Leppert, DO
Internal Medicine · Cape Coral, FLNPI 1912905902
Payments from drug & device makers
Across 234 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$962
- Novo Nordisk$416
- Pfizer$380
- AbbVie$353
- Johnson & Johnson$224
- Lilly USA, LLC$134
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,561100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 76 | $962 |
| Novo Nordisk | 23 | $416 |
| Pfizer | 29 | $380 |
| AbbVie(2 entities) | 21 | $353 |
| Johnson & Johnson | 14 | $224 |
| Lilly USA, LLC | 8 | $134 |
| Amgen(2 entities) | 7 | $131 |
| Amarin Pharma, Inc. | 7 | $130 |
| Astellas Pharma US Inc | 6 | $103 |
| Boehringer Ingelheim | 6 | $103 |
| Novartis | 5 | $76 |
| Merck | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Abbott | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| IBSA Pharma Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Dexcom, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$3,561 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $159,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $101,665 |
| JardianceEmpagliflozin | 53 | $67,314 |
| OzempicSemaglutide | 56 | $60,825 |
| XareltoRivaroxaban | 62 | $58,302 |
| JanuviaSitagliptin Phosphate | 27 | $43,457 |
| MounjaroTirzepatide | 39 | $41,530 |
| TrulicityDulaglutide | 15 | $37,815 |
| ProliaDenosumab | 20 | $34,598 |
| MyrbetriqMirabegron | 20 | $23,733 |
| EntrestoSacubitril/Valsartan | 21 | $21,576 |
| FarxigaDapagliflozin Propanediol | 11 | $18,880 |
| Repatha SureclickEvolocumab | 15 | $14,099 |
| GemtesaVibegron | 12 | $13,664 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $380 | $162,441147 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $962 | $115,160106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $134 | $79,34554 claims |
| Boehringer IngelheimJardiance | $103 | $67,31453 claims |
| Novo NordiskOzempic | $416 | $60,82556 claims |
| Johnson & JohnsonXarelto | $224 | $58,30262 claims |
| MerckJanuvia | $65 | $43,45727 claims |
| AmgenProlia | $131 | $34,59820 claims |
| Astellas Pharma US IncMyrbetriq | $103 | $23,73320 claims |
| NovartisEntresto | $76 | $21,57621 claims |
| AbbVieSynthroid | $353 | $2,53872 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Cape Coral
- Jose Cevallos YepezCape Coral$4.2M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.